Business Description
Vicore Pharma Holding AB
ISIN : SE0007577895
Compare
Compare
Traded in other countries / regions
VICO.Sweden6Y4.Germany IPO Date
2020-07-21Description
Vicore Pharma Holding AB is as a clinical-stage pharmaceutical company focused on severe lung diseases. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). Its C21 is a small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2a development for IPF. The company also has an investigational medical device in clinical development namely, Almee which is a digital therapeutic leveraging cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis.
Financial Strength
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.9 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 24.81 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -6.4 | |||||
3-Year EPS without NRI Growth Rate | -5.9 | |||||
3-Year FCF Growth Rate | -4.5 | |||||
3-Year Book Growth Rate | -11.4 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 37.08 | |||||
9-Day RSI | 41.25 | |||||
14-Day RSI | 45.45 | |||||
6-1 Month Momentum % | 54.13 | |||||
12-1 Month Momentum % | 44.66 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 10.74 | |||||
Quick Ratio | 10.74 | |||||
Cash Ratio | 10.2 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -22.7 | |||||
Shareholder Yield % | -23.33 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -222.22 | |||||
Net Margin % | -204.27 | |||||
FCF Margin % | -140.04 | |||||
ROE % | -52.26 | |||||
ROA % | -47.2 | |||||
ROIC % | -371.15 | |||||
ROC (Joel Greenblatt) % | -667746.88 | |||||
ROCE % | -52.17 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 20.58 | |||||
PB Ratio | 4.39 | |||||
Price-to-Tangible-Book | 4.42 | |||||
EV-to-EBIT | -8.82 | |||||
EV-to-Forward-EBIT | -4.75 | |||||
EV-to-EBITDA | -8.82 | |||||
EV-to-Forward-EBITDA | -4.75 | |||||
EV-to-Revenue | 18.09 | |||||
EV-to-FCF | -12.67 | |||||
Price-to-Net-Current-Asset-Value | 4.42 | |||||
Price-to-Net-Cash | 4.66 | |||||
Earnings Yield (Greenblatt) % | -11.34 | |||||
FCF Yield % | -6.94 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Vicore Pharma Holding AB Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 9.211 | ||
EPS (TTM) (€) | -0.19 | ||
Beta | 0.61 | ||
Volatility % | 48.9 | ||
14-Day RSI | 45.45 | ||
14-Day ATR (€) | 0.063253 | ||
20-Day SMA (€) | 1.812 | ||
12-1 Month Momentum % | 44.66 | ||
52-Week Range (€) | 1.034 - 2.08 | ||
Shares Outstanding (Mil) | 111.73 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Vicore Pharma Holding AB Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Vicore Pharma Holding AB Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Vicore Pharma Holding AB Frequently Asked Questions
What is Vicore Pharma Holding AB(STU:6Y4)'s stock price today?
The current price of STU:6Y4 is €1.72. The 52 week high of STU:6Y4 is €2.08 and 52 week low is €1.03.
When is next earnings date of Vicore Pharma Holding AB(STU:6Y4)?
The next earnings date of Vicore Pharma Holding AB(STU:6Y4) is 2024-08-22.
Does Vicore Pharma Holding AB(STU:6Y4) pay dividends? If so, how much?
Vicore Pharma Holding AB(STU:6Y4) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |